FOOD & DRUG ADMINISTRATION MAHARASHTRA STATE, MUMBAI 400 051

CERTIFICATE OF A PHARMACEUTICAL PRODUCT [1]

This certificate conforms to the format recommended by the World Health Organisation
(General instructions and explanatory notes attached)

No. of certificate : **COPP/CERT/PD/109187/2021/11/38483/188495** **Valid Upto :28 Nov 2024**

Exporting Country : INDIA

Importing Country : **As per Annexure**

1. Name and dosage form of product : **VIROPIL**
Dolutegravir, Lamivudine and Tenofovir Disoproxil Fumarate Tablets (50 / 300 / 300 mg)

1.1 Active ingredient(s)[2] and amount (s) per unit dose [3]: Each film coated tablet contains

Lamivudine USP 300 mg	Dolutegravir Sodium Equivalent to Dolutegravir 50 mg	Excipients qs
Tenofovir Disoproxil Fumarate .....300 mg Equivalent to Tenofovir Disoproxil 245 mg		
Colour:Titanium Dioxide USP		

For complete qualitative composition including excipients :[4]

1.2 Is this product licensed to be placed on the market for use in the exporting country ?[5] Yes ☒ No ☐

1.3 Is this product actually on the market in the exporting country ? Yes ☒ No ☐ Unknown ☐

2A.1 Number of product license:[7] **PD149 In Form 25**
and date of issue: **01 Jun 2018**
and Revised date: **04 Sep 2018**

2A.2 Product License holder (Name and address) :
EMCURE PHARMACEUTICALS LTD PLOT NO. P1 AND P2, I.T.B.T. PARK PHASE-II, M.I.D.C. HINJAWADI PUNE 411057 MAHARASHTRA STATE, INDIA

2A.3 Status of product-license Holder :[8]
A ☒ B ☐ C ☐

2A.3.1 For categories b and c the name and address of the manufacturer producing the dosage form is:[9]

2A.4 Is summary basis of Approval appended ?[10]
Yes ☐ No ☒

2A.5 Is the attached, officially approved product information complete and consonant with the license ?[11]
Yes ☐ No ☐ Not Provided ☒

2A.6 Applicant for certificate if different from License holder :[12]
Not Applicable

2B.1 Applicant for certificate (name and address) :

2B.2 Status of applicant :
A ☐ B ☐ C ☐

2B.2.1 For categories b and c the name and address of the manufacturer producing the dosage form is[9]

2B.3. Why is marketing authorization lacking ?
☐ Not required ☐ Not requested ☐ Under Consideration ☐ Refused

2B.4 Remarks :[13]

COMMISSIONER, FOOD AND DRUGS ADMINISTRATION MAHARASHTRA STATE

3. Does the certifying authority arrange for periodic inspection of the manufacturing plant in which the dosage form is produced ?
if no or not applicable proceed to question 4. Yes ☒ No ☐ **Not Applicable**[14] ☐

3.1 Periodicity of routine inspections(years) : **Once a year**

3.2 Has the manufacture of this type of dosage form been inspected ? Yes ☒ No ☐

3.3 Do the facilities and operations conform to GMP as recommended by World Health Organisation ?[15]
Yes ☒ No ☐ Not Applicable [14] ☐

4. Does the information submitted by the applicant satisfy the certifying authority on all aspects of the manufacture of the product ?[16]
Yes ☒ No ☐

If no, explain :

Address of certifying authority :
Food & Drug Administration, M.S.
Bandra-kurla Complex,
Bandra (E), Mumbai – 400 051.
Maharashtra,INDIA.
Tel: +91-22-26592363/64/65
Fax: +91-22-26591959
5CME1111091872021121710 1

Name of the Authorised person : **D. R. GAHANE**

Signature :

Stamp and Date : **Joint Commissioner (HQ) & Controlling Authority**
Food & Drug Administration, M.S.
Bandra (E), Mumbai.
Maharashtra State, India
Date:**17 Dec 2021**

GENERAL INSTRUCTION :

Please refer to the guidelines for full instruction on how to complete this form and information on the implementation of the scheme.The forms are suitable for generation by computer. They should always be submitted as hard copy, with responses printed in type rather than hand written.Additional sheets should be appended, as necessary, to accommodate remarks and explanations .

EXPLANATORY NOTES :

1. This certificate, which is in the format recommended by WHO, establishes the status of the pharmaceutical product and of the applicant for the certificate in the exporting country .It is for a single product only since manufacturing arrangements and approved information for different dosage forms and different strengths can vary.
2. Use, whenever possible, International Nonproprietary Names (INNS) or national nonproprietary names.
3. The formula (complete composition) of the dosage form should be given on the certificate or be appended.
4. Details of quantitative composition are preferred, but their provision is subject to the agreement of the product-Licence holder.
5. When applicable, append details of any restriction applied to the sale, distribution, or administration of the product that is specified in the product Licence.
6. Sections 2A and 2B are mutually exclusive.
7. Indicate, when applicable, if the Licence is provisional, or the product has not yet been approved.
8. Specify whether the person responsible for placing the product on the market :
   (a) manufactures the dosages form
   (b) packages and / or labels a dosage form manufactured by an independent company : or
   (c) is involved in none of the above .
9. This information can be provided only with the consent of the product - Licence holder or, in the case of non-registered products, the applicant . Non-completion of this section indicates that the party concerned has not agreed to inclusion of this information.It should be noted that information concerning the site of production is part of the product Licence. If the production site is changed the Licence must be updated or it will cease to be valid.
10. This refers to the document, prepared by some national regulatory authorities, that summarizes the on which the product has been licensed.
11. This refers to product information approved by the competent national regulatory authority, such as a summary of product characteristics (SPC).
12. In this circumstance, permission for issuing the certificate is required from the product Licence holder. This permission must be provided to the authority by the applicant.
13. Please indicate the reason that the applicant has provided for not requesting registration:
    (a) the product has been developed exclusively for the treatment of conditions – particularly tropical diseases—not endemic in the country of export:
    (b) the product has been reformulated with a view to improving its stability under tropical conditions:
    (c) the product has been reformulated to exclude excipients not approved for use in pharmaceutical products in the country of import:
    (d) the product has been reformulated to meet a different maximum dosage limit for an active ingredient
    (e) any other reason, please specify.
14. Not applicable means that the manufacture is taking place in a country other than that issuing the product certificate and Inspection is conducted under the aegis of the country of manufacture.
15. The requirements for good practices in the manufacture and quality control of drugs referred to the certificate are those included in the thirty- second report of the Expert Committee on specifications for Pharmaceutical Preparations (WHO Technical Report Series, No.823 , 1992 , Annex 1) Recommendations specifically applicable to biological products have been formulated by the WHO Expert Committee on Biological Standardization (WHO Technical Report Series , No . 822, 1992, Annex 1)
16. The Section is to be completed when the product - licence holder or applicant conforms to status (b) or (c) as described in note 8 above. It is of particular importance when foreign contractors are involved in the manufacture of the product . In these circumstances the applicant should supply the certifying authority with information to identify the contracting parties responsible for each stage of manufacture of the finished dosage form and the extent and nature of any controls exercised over each of these parties.

The layout for this Model Certificate is available on diskette in Word Perfect from the Division of Drug Management and Policies. World Health Organization, 1211 Geneva 27, Switzerland.



Food & Drugs Administration, Maharashtra State, Mumbai 400051, India

Annexure to the Certificate of a Pharmaceutical Product

No. of Certificate : **COPP/CERT/PD/109187/2021/11/38483/188495** **Valid up to: 28 Nov 2024**

Name of the Product License Holder : **EMCURE PHARMACEUTICALS LTD PLOT NO. P1 AND P2, I.T.B.T. PARK PHASE-II, M.I.D.C. HINJAWADI PUNE 411057**

Name of the Product : **MAHARASHTRA STATE, INDIA**

: **VIROPIL**

: **Dolutegravir, Lamivudine and Tenofovir Disoproxil Fumarate Tablets (50 / 300 / 300 mg)**

List of Countries For Export

Afghanistan	Bosnia and Herzegovina	Czechoslovakia	Grenada	Kosovo	Micronesia	Philippines	South Sudan	Turkey
Albania	Botswana	Denmark	Guatemala	Kurdistan	Moldova	Poland	Spain	Turkmenistan
Algeria	Brazil	Djibouti	Guinea	Kuwait	Monaco	Porte Rico	Sri Lanka	Turks and Calicos
Andorra	British Virgin	Dominica	Guinea-Bissau	Kyrgyzstan	Mongolia	Portugal	St. Kitties	Tuvalu
Anglia	Brunei	Dominican Republic	Guyana	LaO PDR	Monstserrat	Qatar	st. Kitties and Nevi	Uganda
Angola	Brunei Darussalam	DR Congo	Haiti	Laos	Montenegro	R.D. Congo	St. Lucia	Ukraine
Anguilla	Bulgaria	East Timor	Herzegovina	Latvia	Morocco	Rep. of Congo	St. Maarten	UNHCR
Antigua	Burkina Faso	Ecuador	Holland	Lebanon	Mozambique	Reunion	St. Vincent	UNICEF
Antigua and Barbuda	Burundi	Egypt	Holy See	Leone	Myanmar	RITES	St. Vincent and the Grenadines	United Arab Emirates
Argentina	Cabo Verde	El Salvador	Honduras	Lesotho	Namibia	Romania	Sudan	United Kingdom
Armenia	Cambodia	England	Hong-Kong	Liberia	Nauru	Russia	Sultanate of Oman	United State
Aruba	Cameroon	Equatorial Guinea	Hungary	Libya	Nepal	Rwanda	Suriname	UNOPS
Australia	Canada	Eritrea	Iceland	Liechtenstein	Netherlands	Samao	Swaziland	Uruguay
Austria	Cape Verde	Estonia	India	Lithuania	New Zealand	San Marino	Swedan	Uzbekistan
Azerbaijan	Cayman Island	Ethiopia	Indonesia	Luxembourg	Nicaragua	Sao Tome and Principe	switzerland	Vanuata
Bahamas	Central African Republic	Fiji	Iran	Macau	Niger	Saudi Arabia	Syria	Vatican City
Bahrain	Chad	Fiji Island	Iraq	Macedonia	Nigeria	Senegal	Taiwan	Venezuela
Bangladesh	Chile	Finland	Ireland	Madagascar	North Korea	Serbia	Tajikistan	Vietiane
Barbados	China	France	Israel	Malawi	Norway	Seychelles	Tanzania	Vietnam
Belarus	Colombia	French Guiana	Italy	Malaysia	Oman	Sierra Leone	Tchad	Western Samoa
Belgium	Comoros	Gabon	Ivory Coast	Maldives	PAHO	Singapore	Thailand	WHO
Belize	Congo	Gambia	Jamaica	Mali	Pakistan	Slovakia	The Netherlands	Yemen
Belorussia	Costa Rica	Georgia	Japan	Malta	Palau	Slovenia	Timor Leste	Yugoslavia
Benin	Croatia	Germany	Jordan	Marshal Island	Palestine	Solomom Island	Togo	Zaire
Bermuda	Cuba	Ghana	Kazakhstan	Mauritania	Panama	Somalia	Tongo	Zambia
Bhutan	Curacao	Global Fund	Kenya	Mauritius	Papua New Guinea	South Africa	Trinidad & Tobago	Zanzibar
Bolivia	Cyprus	Grand Cayman	Kiribati	Micronesia	Paraguay	South Korea	Tunisia	Zimbabwe
Bosnia	Czechia	Greece	Kosovo	Mexico	Peru			

Address of certifying authority :
Food & Drug Administration, M.S.
Bandra-kurla Complex,
Bandra (E), Mumbai – 400 051.
Maharashtra,INDIA.
Tel: +91-22-26592363/64
Fax: +91-22-26591959

5CME1111091872021121710 1

Name of the Authorised person : **D. R. GAHANE**

Signature :

Seal, Stamp and Date : **Joint Commissioner (HQ) & Controlling Authority**
Food & Drug Administration, M.S.
Bandra (E), Mumbai.
Maharashtra State, India
Date:**17 Dec 2021**

Emcure

Date: 12.03.2021

To,
Medicines and Medical Devices Agency (ANDM)
Moldova

SUB: Fast Track Registration of Viropil (Dolutegravir, Lamivudine, Tenofovir Disoproxil Fumarate tablets 50mg/300mg/300 mg).

Dear Sir/Mam,
Emcure Pharmaceuticals Limited, India, presents its compliments to the **Medicines and Medical Devices Agency (ANDM), Moldova**

We draw your attention to the above mentioned Viropil registration dossier submission to **Medicines and Medical Devices Agency (ANDM), Moldova.**

We are happy to inform you that this product has been reviewed by the WHO Prequalification unit and is prequalified on 22 February 2021 by World Health Organisation, Geneva, Switzerland with the reference number as **HA722.** We would further like to inform that the manufacturing process, process controls, packing details are same for WHO submission batches and one filed with your esteemed health agency.

We appeal through your good offices to review our dossier on priority/fast track for this product to be made available in **Moldova.**

Enclosed Approval Letter and link provided below:

https://extranet.who.int/pqweb/medicine/4327

Thanking you for your co-operation.

For Emcure Pharmaceuticals Ltd.,

12 March 2021

EMCURE PHARMACEUTICALS LTD. (INDIA)

Dr. Binnu Singh
Head- Regulatory Affairs (Emerging Market)

Emcure Pharmaceuticals Limited

Registered Office
Emcure House, T-184,
M.I.D.C., Bhosari, Pune 411 026 (India)
Tel: 91-20-30610000,
Fax: + 91-20-30610111
E-mail: corporate@emcure.co.in
CIN - U24231PN1981PLC024251

Drug Product Manufacturing
Plot No. P-1 and P-2,
I. T.B.T. Park, Phase-II,
M.I.D.C., Hinjawadi,
Pune – 411057 (India)
Tel: + 91-20-39821300,
Fax No: + 91-20-39821460/39821445
E-mail: ra@emcure.co.in

Drug Substance Manufacturing
Plot no. D-24, M.I.D.C.,
Kurkumbh Industrial Area
Taluka - Daund, District- Pune 413802
E-mail: corporate@emcure.co.in

World Health Organization

20, AVENUE APPIA – CH-1211 GENEVA 27 – SWITZERLAND – TEL CENTRAL +41 22 791 2111 – FAX CENTRAL +41 22 791 3111 – WWW.WHO.INT

Tel. direct: +41 22 791 37 17
Fax direct: +41 22 791 47 30
E-mail : prequalassessment@who.int

In reply please refer to: HA722-0/MS/EG

Your reference:

Dr. Binnu Singh
Deputy General Manager - Regulatory Affairs
Emcure Pharmaceuticals Ltd
A-201Ganga Osian Square Survey No# 249-250
Wakad
Pimpri - Chinchwad 411057
Pune
Maharashtra
Inde

22 February 2021

Dear Dr. Singh,

WHO Prequalification Unit – Medicines Assessment
FPP Prequalification – Letter of Prequalification

Application number: HA722-0

I refer to your letter expressing Emcure Pharmaceuticals Ltd's interest to participate in the "Procedure for assessing the acceptability, in principle, of pharmaceutical products for purchase by United Nations agencies", as adopted in 2001 by the Thirty-seventh World Health Organization (WHO) Expert Committee on Specifications for Pharmaceutical Preparations, and published in the WHO Technical Report Series No. 908, and amended subsequently in the Forty-fifth report, as published in the WHO Technical Report Series No. 961 in 2011.

Thank you for submitting the data and information requested and for your voluntary participation in this quality assessment procedure. The review of your company's product dossier on:

- **HA722 - Dolutegravir (Sodium)/Lamivudine/Tenofovir disoproxil fumarate Tablet, Film-coated 50mg/300mg/300mg**

has been completed and following inspection of the facilities used for the manufacture and testing of this product, it has been found to meet the norms and standards recommended by WHO and is acceptable, in principle, for procurement by UN agencies.

This conclusion is based on information available to WHO at the current time, i.e. the information in the submitted dossier and on the status of current good manufacturing, clinical and laboratory practices at the facilities used for the manufacture and testing of the product. Please note, however, that this decision may change based on new information that may become available to us. Therefore, in accordance with and subject to the Guiding Principles of Prequalification, the product will now be included in the list of medicinal products, as manufactured at the specified manufacturing sites, which are considered to be acceptable, in principle, for procurement by UN organizations. This list is published by WHO at www.who.int/prequal.

Please note that inclusion in the list cannot be construed as WHO approval or endorsement and does not necessarily mean that the listed products will actually be procured from the suppliers mentioned. The list, and the WHO name, emblem and/or acronym may not, furthermore, be used by the applicants, manufacturers, suppliers or any other parties for commercial or promotional purposes.

ENCLS: (2)